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Abstract Farnesol preferentially inhibits proliferation and
induces apoptosis of tumour-derived but not non-transformed
cell lines. We investigated whether farnesol induces apoptosis of
blasts from patients with acute myeloid leukaemia (AML) and
leukaemic cell lines, as compared with normal, human primary
haemopoietic cells. We show that 30 WM farnesol causes
apoptosis of leukaemic cell lines of T- and B-lymphocyte,
myeloid or erythroid lineages and primary blasts obtained from
patients with AML. However, the same concentration did not kill
primary monocytes, or quiescent or proliferating T-lymphocytes.
We conclude that farnesol selectively kills AML blasts and
leukaemic cell lines in preference to primary haemopoietic cells.
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1. Introduction
Farnesol is a member of a class of compounds known as
non-sterol isoprenoids [1]. Sterol and non-sterol isoprenoids
are natural products which are produced from a common
precursor, mevalonate, and are required for a number of cel-
lular functions, such as cell signalling, protein synthesis, mem-
brane integrity, cell proliferation and apoptosis [2]. These di-
verse cellular functions are mediated via the production from
mevalonate of a number of compounds including cholesterol,
ubiquinone, farnesyl and geranylgeranyl isoprenoids, dolichol
and retinoic acid precursors [2,3]. Farnesyl diphosphate and
geranylgeranyl diphosphate are necessary for protein prenyla-
tion, which is a post-translational modi¢cation of proteins
such as Ras and which is required for their targeting to the
plasma membrane and hence activity [4].
Cancer chemoprevention using monoterpenes is an active
area [5]. The oily extracts from natural sources such as or-
anges, lemons and lemon grass contain a number of terpenes
that possess anti-carcinogenic activity, including limonene,
menthol and carvone. However, terpenoid compounds that
possess hydroxy groups are generally more active than the
corresponding terpene hydrocarbons. Examples include the
inhibition of human MIA PaCa2 pancreatic tumour cells by
the terpenoid alcohols perillyl alcohol, geraniol and farnesol
at respective in vivo concentrations of 300, 100 and 25 WM [6].
Farnesol and geranylgeraniol have been shown to arrest the
proliferation of a number of cell lines [6,7] and to induce
apoptosis of several tumour-derived cell lines [8^10]. It was
also reported that farnesol preferentially caused apoptosis of
tumour-derived cell lines rather than in lines derived form
non-neoplastic cells [10]. In a recent study [11], it was shown
that farnesol and geranylgeraniol induced G0/G1 cell cycle
arrest and apoptosis of a human lung adenocarcinoma cell
line independent of protein prenylation. Several studies have
shown that these compounds inhibit choline phosphotransfer-
ase and thereby prevent phosphatidyl choline biosynthesis
[9,12^14].
Another likely mode of action of such terpenoids is by in-
hibition of protein prenyltransferases [15]. Inhibition of farne-
syltransferase (Ftase) has been shown to cause tumour regres-
sion in animal models. Such enzyme inhibition was strongly
reinforced by the recent report of the crystal structure of
protein Ftase [16]. Ftase catalyses the lipidation of Ras at
the carboxy terminus and other cellular signal transduction
proteins. The size, shape and constitution of one cleft of Ftase
is highly suited to the docking of a farnesyl isoprenoid. Far-
nesol induces apoptosis in lymphoma, cervical carcinoma and
other cell types, and its relatively high anticarcinogen activity
amongst simple terpenoid alcohols led us to study its e¡ects
on leukaemic cells.
Farnesol inhibits cell proliferation and induces apoptosis
preferentially of neoplastic cells, albeit of cell lines. Therefore,
we investigated whether farnesol causes cell cycle inhibition
and apoptosis of human primary haemopoietic cells as com-
pared with leukaemic cell lines and blasts from patients with
myeloid leukaemia (AML).
2. Materials and methods
2.1. Reagents
Chemicals were obtained from Sigma unless stated otherwise. Far-
nesol (trans, trans-farnesol ([2E, 6E]-3,7,11-trimethyl-2,6,10-dodeca-
trien-1-ol)) and taxol were diluted in dimethyl sulfoxide (DMSO) pri-
or to use.
2.2. Cells and cell culture
2.2.1. Normal, primary haemopoietic cells. All cells were isolated
form the blood of haematologically normal, healthy volunteers. Cell
isolation and culture methods have been described previously [17,18]
with additional details as described below. Brie£y, mononuclear cells
were obtained by Ficoll^Hypaque gradient centrifugation and mono-
cytes were either obtained by adhesion to plastic or by selection with
anti CD14-conjugated magnetic beads, according to the manufactur-
er’s instructions (Miltenyi). Primary T-lymphocytes were obtained
after the monocytes had been removed (mixture of T- and B-lympho-
cytes) and were at least 80% pure, as determined by £ow cytometry
with CD3, CD4, CD8, CD14, CD19 and CD45. The puri¢ed T-cells,
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which are in G0 [19], were cultured at 1U106 cells/ml in RPMI/10%
FCS (Gibco-BRL)/penicillin/streptomycin. Where indicated, they were
stimulated to enter G1 with 1 Wg/ml phytohaemagglutinin (PHA)
(Glaxo-Wellcome) for 60 h and proliferating cells were obtained by
adding 20 ng/ml interleukin-2 (IL-2) (Murex) for 5^7 days. During
this period cells were kept between 0.8^2U106/ml by adding fresh
medium containing IL-2.
2.2.2. Leukaemic blasts. Blood was obtained from patients with
acute myeloid leukaemia before chemotherapy. All the samples used
had a high blast count (s 70%; as determined by staining with May
Grunwald Giemsa (MGG) stain) and the mononuclear cells were
puri¢ed by Ficoll^Hypaque gradient centrifugation. These were cul-
tured in RPMI-1640/10% (v/v) FCS/penicillin/streptomycin containing
50 ng/ml each of GM-CSF, IL-3 and SCF.
2.2.3. Cell lines. Daudi (obtained from Dr Ian Kerr, London),
Jurkat and HL-60 cells (from Dr Pamela Roberts, London) were
maintained between 2^10U105 cells/ml in RPMI/10% (v/v) FCS and
were split to 2^4U105 cells/ml 24 h before each experiment. TF-1 cells
(from Dr Kitamura, Tokyo) were maintained between 5^50U104/ml
in RPMI/10% (v/v) FCS containing 10 ng/ml GM-CSF.
2.3. Counting viable cells
The proportion of viable cells which exclude trypan blue and dead
cells staining blue was determined by counting at least 100 cells for
each sample with an improved Neubauer chamber.
2.4. Flow cytometry
Cells in each cell cycle phase were quanti¢ed by two-colour £ow
cytometry of DNA (stained with propidium iodide (PI)) and total cell
protein (stained with £uorescein isothiocyanate (FITC)) [20,21]. The
proportion of cells undergoing apoptosis with sub-G1 DNA and low
protein staining [22] was also determined. Analysis was carried out
using an Epics-Elite £ow cytometer (Coulter Electronics). Doublets of
cells in G1 can contaminate the G2/M fraction and doublets of apop-
totic cells can contaminate the S-phase fraction. Doublets were ex-
cluded as far as possible by only including cells which were within
linear gates for forward scatter vs forward scatter peak, for FITC
staining vs FITC peak and also for PI staining vs PI peak.
2.5. Staining slides
Slides of each cell sample (0.5^1U105 cells) were prepared by cy-
tocentrifugation (Shandon cytocentrifuge 3) for 7 min at 700 rpm.
These were left to dry at room temperature for 24 h and were then
stored at 320‡C. After thawing, each slide was stained with MGG
stain.
3. Results
3.1. Induction of apoptosis of leukaemic cell lines
In order to ascertain the concentration of farnesol which
causes cell cycle arrest and apoptosis we cultured the follow-
ing leukaemic cell lines: Jurkat (acute T-cell leukaemia), Dau-
di (B-lymphocyte from a patient with Burkitts’ lymphoma),
HL-60 (acute pro-myelocytic leukaemia) and TF-1 (erythro-
leukaemic cell line derived from bone marrow) in the presence
of 30^75 WM farnesol or diluent controls. After 24 and 48 h
we determined the number of live and dead cells by manual
counting. Also, samples were stained for £ow cytometric anal-
ysis of DNA and protein content in order to determine the
percentage in di¡erent cell cycle phases as well as those which
had died by apoptosis. A signi¢cant number of dead cells were
detected at 24 and 48 h in cultures of Jurkat cells containing
greater than 15 WM farnesol, as judged by trypan blue stain-
ing, and this was increased at higher concentrations of the
drug (Fig. 1A). Farnesol caused an increase in cells with a
sub-diploid DNA and low protein content characteristic of
cells undergoing apoptosis. An example of such an experiment
Fig. 1. A: Farnesol causes cell death of Jurkat T-cells. Jurkat cells
were cultured in the presence of 30, 45 or 60 WM farnesol, with
DMSO (equivalent to that added in the the 60 WM farnesol sample)
or with no addition, samples were taken after 24 and 48 h and via-
ble cells which exclude trypan blue and dead cells which take up
trypan blue were counted manually. The percentage of dead cells
for each condition is shown (mean þ S.E.M., n = 3). B: Flow cyto-
metric analysis of Jurkat cells. Jurkat cells were cultured for 48 h
with: a. no addition, b. DMSO, c. 15 WM, d. 30 WM or e. 45 WM
farnesol and samples were analysed for DNA and total protein con-
tent as described in Section 2. Cells in the G1, S and G2/M phases
of the cell cycle are indicated as well as those undergoing apoptosis
which have sub-G1 DNA staining and low protein content.
Table 1













24 h Sub G1 5.6 4.5 7.4 26.3 37.5 41.8 41.0
G1 50.6 51.0 49.0 41.9 33.6 23.5 25.0
S 31.3 31.7 33.2 26.3 23.7 25.5 24.7
G2+M 31.3 13.1 10.9 8.8 5.9 8.9 9.2
48 h Sub G1 6.9 7.7 9.5 29.5 53.1 63.7 70.8
G1 52.4 52.3 54.5 41.8 24.4 19.5 15.4
S 30.5 29.2 27.0 21.4 16.8 14.0 11.5
G2+M 11.0 10.9 9.1 7.3 4.5 3.2 2.6
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is shown in Fig. 1B and the data from four experiments are
tabulated (Table 1). Data for TF-1 cells at 45 WM farnesol are
shown in Table 2 and similar data showing signi¢cant cell
death were obtained for both HL-60 and Daudi cells (data
not shown). Our results are within the concentration range
reported by others for inducing apoptosis of the CEM-1 acute
leukaemia T-cell line [8].
3.2. Farnesol does not cause apoptosis of primary lymphocytes
or monocytes
Next we determined whether the same concentrations of
farnesol induced apoptosis of puri¢ed monocytes or T-lym-
phocytes isolated from peripheral blood. Farnesol at 15 or 30
WM caused little death of quiescent, primary T-lymphocytes
over a 48 h period, as judged either by trypan blue exclusion
(not shown) or £ow cytometric analysis of DNA content
(6 7% dead; Fig. 2A). In order to determine whether another
primary haemopoietic cell of a di¡erent lineage was killed by
farnesol we isolated monocytes from peripheral blood and
cultured them in up to 60 WM farnesol for 48 h. We did not
detect apoptosis above control values, as judged by £ow cy-
tometry of DNA content (Fig. 2B). Thus signi¢cantly fewer
primary T-lymphocytes or monocytes die in response to far-
nesol than the any of the leukaemic cell lines tested.
Both T-lymphocytes and monocytes are quiescent and the
di¡erence in the e¡ects of farnesol between these and leukae-
mic cell lines could occur if farnesol preferentially kills pro-
liferating cells. In order to address this possibility, primary
T-lymphocytes proliferating in IL-2 were cultured with 30^
75 WM farnesol for 24 and 48 h and the same assays were
performed. As shown in Fig. 2C,D, farnesol caused 6 10%
Fig. 2. A: Farnesol does not cause apoptosis of primary T-lymphocytes. Primary T-lymphocytes isolated from peripheral blood were cultured
under the conditions shown for 24 and 48 h and samples were analysed as in Fig. 1B. The percentage of apoptotic cells with sub-G1 DNA
staining and low protein content is shown. B: Farnesol does not cause apoptosis of primary monocytes. Monocytes were isolated from periph-
eral blood, cultured under the conditions indicated for 48 h and analysed as in Fig. 1B. The percentages in G0/G1, S+G2/M or undergoing
apoptosis are shown (representative of n = 2). C and D: Farnesol does not cause apoptosis of proliferating primary T-cells. Peripheral blood T-
cells were cultured in PHA and then stimulated to proliferate with IL-2 as described in Section 2. Samples were taken at 24 h (C) and 48 h
(D) and analysed as described for Fig. 1B (representative of n = 3).
Fig. 3. A^C: Farnesol causes cell death of blasts isolated form pa-
tients with AML. AML blasts were isolated as described in Section
2 and cultured with SCF, IL-3 and GM-CSF. Farnesol or DMSO
were added as indicated and cells were counted manually after 24
and 48 h. The percentages of dead cells which took up trypan blue
are shown for three patients.
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apoptosis above the controls and the percentage undergoing
apoptosis did not increase at 72 h (not shown). We also cul-
tured the same cells with taxol which caused cell cycle arrest
in G2/M and did induce apoptosis of these primary cells.
Thus, farnesol selectively kills leukaemic cell lines and does
not induce apoptosis simply because cells are proliferating.
3.3. Farnesol reduces the number of viable AML blasts
In order to determine whether farnesol would kill primary
leukaemic cells we cultured blasts isolated from three patients
with AML with 30 and 60 WM farnesol and counted viable
cells after 24 and 48 h. In each case, both concentrations of
farnesol caused signi¢cant cell death of cells from each of the
patients analysed, as compared with the diluent controls (Fig.
3A^C). We note, however, that the proportion of dead cells
detected varied between 25 and 90% for the samples tested.
Staining cytocentrifuge preparations showed that there were
signi¢cant numbers of cell debris in the farnesol-treated sam-
ples as compared with the diluent controls (Fig. 4C^E). Slides
of TF1 cells and proliferating primary T-lymphocytes cultured
with farnesol were also stained and cell debris was present in
the sample of farnesol-treated TF1 cells (Fig. 4A) but not in
farnesol-treated T-lymphocytes (Fig. 4B). We concluded that
farnesol induces apoptosis of blasts isolated from AML pa-
tients.
4. Discussion
In this study we have investigated whether farnesol selec-
tively kills leukaemic cells as compared with normal haemo-
poietic controls. To this end we determined the concentration
of farnesol which causes the apoptosis of a panel of leukaemic
cell lines corresponding to haemopoietic cells of di¡erent lin-
eages. We then showed that the same concentration does not
cause the death of normal, primary T-lymphocytes or mono-
Fig. 4. A^E: Cell debris in TF1 and AML blasts treated with farnesol. A: TF1 cells. B: T-lymphocytes proliferating in IL-2. C^E: Three
AML samples were cultured with diluent (DMSO) or with 30 WM farnesol for 72 h (D for 48 h) and cytocentrifuge preparations were stained
with MGG. Cell debris and contaminating red blood cells (RBC) are shown.
Table 2
The e¡ect of farnesol on the percentage of TF1 cells in each cell





24 h Sub G1 32.0 27.2 68.2
G1 42.8 44.4 23.2
S 20.6 22.6 6.0
G2+M 5.2 6.5 2.4
48 h Sub G1 19.1 39.8 90.1
G1 54.8 43.8 8.2
S 18.8 11.9 1.2
G2+M 7.3 4.6 0.2
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cytes. Finally, we have shown that farnesol causes cell death
of blasts obtained from patients with AML. Our data show
that farnesol selectively kills primary leukaemic cells and cell
lines rather than normal primary haemopoietic cells.
Previous work showed that farnesol causes apoptosis of a
range of di¡erent malignant cell lines at concentrations be-
tween 15 and 30 WM [10,13^15]. Our data are consistent
with this and there was signi¢cant cell death after 24 h of
all the leukaemic cell lines tested at these concentrations.
When cells die by apoptosis they lose cytosol by blebbing
and so become smaller and their DNA becomes fragmented.
Thus our two-colour £ow cytometric data also indicate that
apoptosis occurred principally from the G0/G1 phase: we
observed cells with sub-G1 DNA and low protein content
but there was no evidence of cells with sub-G2/M or sub-S-
phase DNA and low protein content. These data are in agree-
ment with the e¡ects of farnesol on the human adenocarcino-
ma cell line, A549 [11].
Farnesol does not induce apoptosis of human primary
T-lymphocytes or monocytes isolated from peripheral blood.
We increased the concentration of farnesol in cultures of qui-
escent T-lymphocytes and even 90 WM farnesol did not cause
apoptosis over the period of study (data not shown). It is clear
also that the proliferation state of the primary cells is not
important since farnesol did not cause apoptosis of either
non-proliferating or proliferating primary T-lymphocytes.
However, it is not clear why farnesol does not kill primary
haemopoietic cells. Others have shown that the e¡ects of
farnesol on cell lines are mediated through the inhibition of
choline phosphotransferase rather than blocking isoprenoid
biosynthesis from mevalonate [10] and can be reversed by
the addition of diacylglycerol or phosphatidyl choline
[11,14]. Further work is required to determine whether farne-
sol inhibits choline phosphotransferase in normal, primary
haemopoietic cells and if so what downstream mechanisms
protect these cells, and why leukaemic cells are susceptible.
Our data show that farnesol does cause primary AML
blasts to die over a period of 24 h. There was variation on
the percentage of cell death between samples from the three
patients, but each was signi¢cantly above the diluent controls.
It is possible that the variation is due to a di¡erence in leu-
kaemic cell type and more extensive studies are now war-
ranted to test whether AML cells of di¡erent FAB-types are
more or less susceptible to farnesol. In conclusion, our studies
show that farnesol causes signi¢cant cell death of leukaemic
cells without a¡ecting normal, primary cells.
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